The Union Health Ministry has mandated doctor’s prescriptions for cough syrups after contamination incidents killed over 300 children abroad, raising questions about India’s pharmaceutical regulation and global reputation. This topic is important for aspirants preparing for GS2 Polity and public health governance issues through civil services coaching.
Who Regulates Drugs?
• Drug Regulation: Governed by the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.
• Global Concern: WHO issued alerts in 2022–23 after ethylene glycol (EG) and diethylene glycol (DEG) contamination in India-made syrups.
• India’s Role: Known as the “world’s pharmacy,” exporting medicines to over 150 countries.
Major Issues
Prescription Requirement
• Syrups removed from Schedule K, now sold only with prescription to reduce misuse and self-medication.
• Limitation: Does not address contamination or manufacturing lapses.
Manufacturing Failures
• Contamination linked to poor raw material testing and weak batch quality checks.
• Indian Pharmacopoeia updated methods post-crisis, but enforcement remains patchy.
• Example: Similar lapses caused deaths in Gambia and Uzbekistan (2022–23).
Regulatory Weakness
• India has 36 State drug controllers, but inspectorates are understaffed.
• Enforcement gaps mean rural areas may ignore prescription rules.
• Pharmaceutical lobby resists stricter testing citing cost burdens on small manufacturers.
Public Health Concerns
• OTC syrups often contain risky combinations (bronchodilators, antihistamines, decongestants).
• American Academy of Pediatrics warns against use in children under six.
• In India, pharmacists act as primary care providers in rural areas, making OTC culture entrenched.
Broader Dimensions
• Global Trade: Weak oversight undermines India’s credibility as a drug exporter.
• Health Equity: Prescription-only rules may limit access in underserved areas.
• Governance: Stronger inspectorate, transparent testing, and accountability are needed.
• Comparative Insight: Countries like the US enforce stringent FDA norms; India must align with global standards.
Conclusion
India cannot remain the “world’s pharmacy” without robust regulatory enforcement and uncompromising drug quality standards.
